Backenroth Samuel 4
4 · Vascular Biogenics Ltd. · Filed Apr 18, 2023
Insider Transaction Report
Form 4
Backenroth Samuel
Chief Financial Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2023-03-31−525,000→ 175,000 total→ Ordinary Shares (525,000 underlying) - Exercise/Conversion
Ordinary Shares
2023-03-31+525,000→ 525,000 total
Footnotes (2)
- [F1]Represents the vesting and settlement of a portion of restricted stock units ("RSUs") previously granted to the Reporting Person. Each RSU represents a contingent right to receive one Ordinary Share, par value NIS 0.01, with an exercise price of NIS 0.01 per Ordinary Share.
- [F2]75% of the RSUs vested on March 31, 2023, with the remaining 25% vesting on August 9, 2024. The RSUs have no expiration date and have an exercise price of NIS 0.01 per Ordinary Share.